Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Fact
Go back to Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Fact| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 51.65 -0.27 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.92 | 52 Week High | $118.49 | |||
| Open | $52.00 | 52 Week Low | $55.00 | |||
| Day High | $52.22 | P/E | N/A | |||
| Day Low | $51.39 | EPS | $-0.56 | |||
| Volume | 2,493,676 | |||||
